Literature DB >> 21204909

5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes.

Barbara Pardini, Rajiv Kumar, Alessio Naccarati, Jan Novotny, Rashmi B Prasad, Asta Forsti, Kari Hemminki, Pavel Vodicka, Justo Lorenzo Bermejo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21204909      PMCID： PMC3141199          DOI： 10.1111/j.1365-2125.2010.03892.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

Review 1.  Cancer pharmacogenetics: polymorphisms, pathways and beyond.

Authors:  Cornelia M Ulrich; Kim Robien; Howard L McLeod
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

2.  Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

Authors:  Valérie Boige; Jean Mendiboure; Jean-Pierre Pignon; Marie-Anne Loriot; Marine Castaing; Michel Barrois; David Malka; David-Alexandre Trégouët; Olivier Bouché; Delphine Le Corre; Isabelle Miran; Claire Mulot; Michel Ducreux; Philippe Beaune; Pierre Laurent-Puig
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

3.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

4.  Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

Authors:  Marie-Christine Etienne-Grimaldi; Gérard Milano; Frédérique Maindrault-Goebel; Benoist Chibaudel; Jean-Louis Formento; Mireille Francoual; Gérard Lledo; Thierry André; May Mabro; Laurent Mineur; Michel Flesch; Elisabeth Carola; Aimery de Gramont
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

Review 5.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

6.  Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.

Authors:  Kyoung-Jin Sohn; Ruth Croxford; Zoe Yates; Mark Lucock; Young-In Kim
Journal:  J Natl Cancer Inst       Date:  2004-01-21       Impact factor: 13.506

7.  Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate.

Authors:  C E Canman; T S Lawrence; D S Shewach; H Y Tang; J Maybaum
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

Review 8.  Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.

Authors:  Marie-Christine Etienne-Grimaldi; Mireille Francoual; Jean-Louis Formento; Gérard Milano
Journal:  Pharmacogenomics       Date:  2007-11       Impact factor: 2.533

9.  MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.

Authors:  S Afzal; S A Jensen; B Vainer; U Vogel; J P Matsen; J B Sørensen; P K Andersen; H E Poulsen
Journal:  Ann Oncol       Date:  2009-05-22       Impact factor: 32.976

10.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.

Authors:  M-C Etienne; K Ilc; J-L Formento; P Laurent-Puig; P Formento; S Cheradame; J-L Fischel; G Milano
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640
View more
  23 in total

1.  Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.

Authors:  Chih-Ching Yeh; Ching-Yu Lai; Shih-Ni Chang; Ling-Ling Hsieh; Reiping Tang; Fung-Chang Sung; Yi-Kuei Lin
Journal:  Int J Clin Oncol       Date:  2017-01-02       Impact factor: 3.402

2.  LOC285629 regulates cell proliferation and motility in colorectal cancer cells.

Authors:  S N Nasir; N Abu; N S Ab Mutalib; M Ishak; I Sagap; L Mazlan; I M Rose; R Jamal
Journal:  Clin Transl Oncol       Date:  2017-11-02       Impact factor: 3.405

3.  Ruthenium(II)-Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs.

Authors:  Catarina Teixeira-Guedes; Ana Rita Brás; Ricardo G Teixeira; Andreia Valente; Ana Preto
Journal:  Pharmaceutics       Date:  2022-06-17       Impact factor: 6.525

Review 4.  Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?

Authors:  Daniela Baracaldo-Santamaría; Juan David Cala-Garcia; Germán José Medina-Rincón; Luis Carlos Rojas-Rodriguez; Carlos-Alberto Calderon-Ospina
Journal:  Antibiotics (Basel)       Date:  2022-05-12

5.  Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo.

Authors:  Qi Xie; Min-Yi Wu; Ding-Xuan Zhang; Yi-Ming Yang; Bao-Shuai Wang; Jing Zhang; Jin Xu; Wei-De Zhong; Jia-Ni Hu
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

6.  Identification of novel germline polymorphisms governing capecitabine sensitivity.

Authors:  Peter H O'Donnell; Amy L Stark; Eric R Gamazon; Heather E Wheeler; Bridget E McIlwee; Lidija Gorsic; Hae Kyung Im; R Stephanie Huang; Nancy J Cox; M Eileen Dolan
Journal:  Cancer       Date:  2012-01-03       Impact factor: 6.860

7.  In vitro additive antitumor effects of dimethoxycurcumin and 5-fluorouracil in colon cancer cells.

Authors:  Huiying Zhao; Qingchun Liu; Saisai Wang; Fang Dai; Xiaofei Cheng; Xiaobin Cheng; Wenbin Chen; Min Zhang; Dong Chen
Journal:  Cancer Med       Date:  2017-06-02       Impact factor: 4.452

8.  Novel proapoptotic agent SM-1 enhances the inhibitory effect of 5-fluorouracil on colorectal cancer cells in vitro and in vivo.

Authors:  Ying Wang; Shoujun Yuan; Linna Li; Dexuan Yang; Chengwang Xu; Shanshan Wang; Danshen Zhang
Journal:  Oncol Lett       Date:  2017-04-19       Impact factor: 2.967

9.  Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.

Authors:  Ji-Young Ahn; Ji-Sun Lee; Hye-Young Min; Ho-Young Lee
Journal:  Oncotarget       Date:  2015-10-20

10.  Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.

Authors:  Tongyou Sun; Tienian Zhu; Xiujun Liang; Shifang Yang; Ruijing Zhao
Journal:  Med Sci Monit       Date:  2018-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.